Recently, it has been found that m6A modification of TPM1 can promote the therapeutic efficacy of prostate cancer by mediating m6A modification [30], which affects the expression level of mRNA by affecting its shearing and translation [31]. Here, TPM1 is linked to prostate carcinoma.